Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study

INTRODUCTION: To date, the efficacy and safety of programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy for patients with extensive-stage SCLC (ES-SCLC), with real-world evidence, stratified on the basis of age and performance status (PS), have not been fully investigated....

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Kenji, Yamada, Tadaaki, Takeda, Takayuki, Shiotsu, Shinsuke, Date, Koji, Harada, Taishi, Tamiya, Nobuyo, Chihara, Yusuke, Hiranuma, Osamu, Yamada, Takahiro, Kanda, Hibiki, Nakano, Takayuki, Morimoto, Yoshie, Iwasaku, Masahiro, Tokuda, Shinsaku, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250020/
https://www.ncbi.nlm.nih.gov/pubmed/35789793
http://dx.doi.org/10.1016/j.jtocrr.2022.100353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250020/
https://www.ncbi.nlm.nih.gov/pubmed/35789793
http://dx.doi.org/10.1016/j.jtocrr.2022.100353

Ejemplares similares